$ANIP
ANI PHARMACEUTICALS INC

2022 Q1 Form 10-Q Financial Statement

#000102302422000008 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $64.48M $60.93M $54.52M
YoY Change 18.26% 6.42% 9.54%
Cost Of Revenue $34.27M $33.90M $19.99M
YoY Change 71.48% 38.13% -8.34%
Gross Profit $30.21M $27.03M $34.54M
YoY Change -12.54% -17.36% 23.48%
Gross Profit Margin 46.85% 44.36% 63.34%
Selling, General & Admin $28.82M $30.71M $17.59M
YoY Change 63.85% 113.68% 28.53%
% of Gross Profit 95.4% 113.6% 50.92%
Research & Development $5.274M $3.140M $2.968M
YoY Change 77.7% -14.67% -53.22%
% of Gross Profit 17.46% 11.62% 8.59%
Depreciation & Amortization $14.56M $13.68M $10.90M
YoY Change 33.57% 25.54% -2.55%
% of Gross Profit 48.19% 50.62% 31.56%
Operating Expenses $34.09M $48.03M $20.56M
YoY Change 65.85% 65.91% 2.64%
Operating Profit -$19.20M -$21.00M $3.045M
YoY Change -730.38% -6444.11% -138.83%
Interest Expense -$6.613M -$4.440M -$2.454M
YoY Change 169.48% 74.12% 20.77%
% of Operating Profit -80.59%
Other Income/Expense, Net -$89.00K -$2.690M -$515.0K
YoY Change -82.72% 1581.25% -5250.0%
Pretax Income -$25.90M -$30.85M $76.00K
YoY Change -34175.0% 1196.34% -100.77%
Income Tax -$5.800M -$6.717M -$10.00K
% Of Pretax Income -13.16%
Net Earnings -$20.13M -$24.14M $86.00K
YoY Change -23506.98% 563.99% -101.23%
Net Earnings / Revenue -31.22% -39.61% 0.16%
Basic Earnings Per Share -$1.27 $0.01
Diluted Earnings Per Share -$1.27 -$1.701M $0.01
COMMON SHARES
Basic Shares Outstanding 16.14M 12.00M
Diluted Shares Outstanding 16.14M 12.02M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.91M $100.3M $25.10M
YoY Change 206.42% 1169.62% 23.04%
Cash & Equivalents $76.91M $100.3M $25.07M
Short-Term Investments
Other Short-Term Assets $7.726M $7.589M $5.900M
YoY Change 30.95% 28.63% 96.67%
Inventory $83.16M $81.69M $59.93M
Prepaid Expenses $7.726M $7.589M $5.922M
Receivables $131.6M $128.5M $91.88M
Other Receivables $1.982M $3.667M $0.00
Total Short-Term Assets $301.4M $321.8M $182.8M
YoY Change 64.88% 88.92% 15.18%
LONG-TERM ASSETS
Property, Plant & Equipment $52.71M $52.67M $40.77M
YoY Change 29.3% 27.63% 0.91%
Goodwill $28.19M $27.89M $3.580M
YoY Change 687.37% 674.67%
Intangibles $281.6M $294.1M $178.9M
YoY Change 57.43% 56.02%
Long-Term Investments
YoY Change
Other Assets $2.434M $2.205M $833.0K
YoY Change 192.2% 174.94% -98.7%
Total Long-Term Assets $443.4M $449.8M $281.0M
YoY Change 57.79% 54.65% -13.12%
TOTAL ASSETS
Total Short-Term Assets $301.4M $321.8M $182.8M
Total Long-Term Assets $443.4M $449.8M $281.0M
Total Assets $744.8M $771.6M $463.8M
YoY Change 60.58% 67.31% -3.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.06M $22.97M $13.77M
YoY Change 60.21% 103.95% 10.15%
Accrued Expenses $8.133M $7.650M $2.381M
YoY Change 241.58% 211.48% -89.08%
Deferred Revenue $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $850.0K $850.0K $14.44M
YoY Change -94.11% -93.58% 21.33%
Total Short-Term Liabilities $79.53M $87.54M $82.77M
YoY Change -3.91% 11.42% 4.24%
LONG-TERM LIABILITIES
Long-Term Debt $286.3M $286.5M $169.0M
YoY Change 69.43% 66.15% -10.16%
Other Long-Term Liabilities $860.0K $7.801M $8.378M
YoY Change -89.74% -46.13% -38.4%
Total Long-Term Liabilities $287.2M $294.3M $177.4M
YoY Change 61.91% 57.45% -12.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $79.53M $87.54M $82.77M
Total Long-Term Liabilities $287.2M $294.3M $177.4M
Total Liabilities $398.8M $412.9M $260.1M
YoY Change 53.29% 55.51% -7.46%
SHAREHOLDERS EQUITY
Retained Earnings -$68.30M -$47.77M -$4.886M
YoY Change 1297.87% 860.68%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $321.2M $333.9M $203.7M
YoY Change
Total Liabilities & Shareholders Equity $744.8M $771.6M $463.8M
YoY Change 60.58% 67.31% -3.81%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$20.13M -$24.14M $86.00K
YoY Change -23506.98% 563.99% -101.23%
Depreciation, Depletion And Amortization $14.56M $13.68M $10.90M
YoY Change 33.57% 25.54% -2.55%
Cash From Operating Activities -$18.94M -$12.18M $20.67M
YoY Change -191.65% 113.4% 1108.65%
INVESTING ACTIVITIES
Capital Expenditures $1.949M -$356.0K $698.0K
YoY Change 179.23% -83.13% -54.65%
Acquisitions
YoY Change
Other Investing Activities -$229.0K -$81.86M -$40.00K
YoY Change 472.5% 818470.0% -99.93%
Cash From Investing Activities -$2.178M -$82.21M -$737.0K
YoY Change 195.52% 3777.97% -98.72%
FINANCING ACTIVITIES
Cash Dividend Paid $405.0K $0.00
YoY Change
Common Stock Issuance & Retirement, Net $1.118M $348.0K
YoY Change 221.26%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.270M 179.4M -2.725M
YoY Change -16.7% -8219.64% -119.62%
NET CHANGE
Cash From Operating Activities -18.94M -12.18M 20.67M
Cash From Investing Activities -2.178M -82.21M -737.0K
Cash From Financing Activities -2.270M 179.4M -2.725M
Net Change In Cash -23.39M 85.05M 17.21M
YoY Change -235.94% -947.07% -141.02%
FREE CASH FLOW
Cash From Operating Activities -$18.94M -$12.18M $20.67M
Capital Expenditures $1.949M -$356.0K $698.0K
Free Cash Flow -$20.89M -$11.83M $19.97M
YoY Change -204.61% 228.58% 11578.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
131625000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
128526000
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001023024
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 anip Class C Special Stock Value
ClassCSpecialStockValue
CY2021Q4 anip Class C Special Stock Value
ClassCSpecialStockValue
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-31812
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ANI PHARMACEUTICALS, INC
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
58-2301143
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
210 Main Street West
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Baudette
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
56623
CY2022Q1 dei City Area Code
CityAreaCode
218
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
634-3500
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
ANIP
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76911000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100300000
CY2022Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
113970000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
105260000
CY2022Q1 us-gaap Inventory Net
InventoryNet
83155000
CY2021Q4 us-gaap Inventory Net
InventoryNet
81693000
CY2022Q1 anip Prepaid Income Taxes Net
PrepaidIncomeTaxesNet
1982000
CY2021Q4 anip Prepaid Income Taxes Net
PrepaidIncomeTaxesNet
3667000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7726000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7589000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
301399000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
321775000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
77677000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75627000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24964000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22956000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52713000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52671000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5000000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
73539000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
67936000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
281573000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
294122000
CY2022Q1 us-gaap Goodwill
Goodwill
28188000
CY2021Q4 us-gaap Goodwill
Goodwill
27888000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2434000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2205000
CY2022Q1 us-gaap Assets
Assets
744846000
CY2021Q4 us-gaap Assets
Assets
771598000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
850000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
850000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
22059000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22967000
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4998000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6225000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3265000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8522000
CY2022Q1 anip Accrued Government Rebates
AccruedGovernmentRebates
4557000
CY2021Q4 anip Accrued Government Rebates
AccruedGovernmentRebates
5492000
CY2022Q1 anip Returned Goods Reserve
ReturnedGoodsReserve
35554000
CY2021Q4 anip Returned Goods Reserve
ReturnedGoodsReserve
35831000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
116000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8133000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7563000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
79532000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87537000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
286307000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
286520000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
32053000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
31000000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
860000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7801000
CY2022Q1 us-gaap Liabilities
Liabilities
398752000
CY2021Q4 us-gaap Liabilities
Liabilities
412858000
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24850000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24850000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
122708
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
82662
CY2022Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
4253000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3135000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
391084000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387844000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68300000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47765000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2712000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3055000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
321244000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
333890000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
744846000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
771598000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64477000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54521000
CY2022Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
34271000
CY2021Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
19985000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5274000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2968000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28817000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17587000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14557000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10898000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
753000
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q1 anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
0
CY2021Q1 anip Cortrophin Pre Launch Charges
CortrophinPreLaunchCharges
38000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
83672000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
51476000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19195000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3045000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6613000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2454000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-89000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-515000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25897000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
76000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5767000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
405000
CY2021Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20535000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16137000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12004000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16137000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12017000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
5767000
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
6405000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5767000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6405000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14363000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6491000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
195700000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1869000
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
348000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6405000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
203712000
CY2021Q4 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
358740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3237000
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1118000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
405000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5767000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2022Q1 anip Stockholders Equity Attributable To Parent And Temporary Equity
StockholdersEquityAttributableToParentAndTemporaryEquity
346094000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3237000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1869000
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-7464000
CY2021Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-279000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14557000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10898000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
982000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
572000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
753000
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3099000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3917000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1462000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-876000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
137000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-379000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1009000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2462000
CY2022Q1 anip Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
-1227000
CY2021Q1 anip Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
-1097000
CY2022Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1685000
CY2021Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-247000
CY2022Q1 anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
-935000
CY2021Q1 anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
846000
CY2022Q1 anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
-248000
CY2021Q1 anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
1792000
CY2022Q1 anip Increase Decrease Of Accrued Expenses Compensation And Others
IncreaseDecreaseOfAccruedExpensesCompensationAndOthers
-4445000
CY2021Q1 anip Increase Decrease Of Accrued Expenses Compensation And Others
IncreaseDecreaseOfAccruedExpensesCompensationAndOthers
-1406000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18942000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20668000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
229000
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
39000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1949000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
698000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2178000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-737000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
750000
CY2021Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2377000
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
405000
CY2021Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1118000
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
348000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2270000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2725000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-23390000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
17206000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105301000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12867000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81911000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30073000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100300000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7864000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5001000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105301000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12867000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76911000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25073000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5000000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5000000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81911000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30073000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5637000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1983000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
112000
CY2022Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
115000
CY2022Q1 anip Accrual For Other Investing And Financing Activities
AccrualForOtherInvestingAndFinancingActivities
0
CY2021Q1 anip Accrual For Other Investing And Financing Activities
AccrualForOtherInvestingAndFinancingActivities
388000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
253000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
218000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. Our four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey, and one is located in Oakville, Ontario, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. </p>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</p>
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64477000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54521000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64477000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54521000
CY2022Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
1300000
CY2021Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
10700000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
100000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
100000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6058000
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2304000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
591000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
177000
CY2022Q1 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
30000
CY2021Q1 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
26000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
6619000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2455000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
86000
CY2021Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
5000
CY2021Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
5000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
405000
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
405000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20535000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
81000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20535000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
81000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16137000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12004000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16137000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12004000
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
13000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16137000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12017000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2500000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
52816000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
51350000
CY2022Q1 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
5560000
CY2021Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
5475000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
615000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
652000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31363000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31969000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
90354000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
89446000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7199000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7753000
CY2022Q1 us-gaap Inventory Net
InventoryNet
83155000
CY2021Q4 us-gaap Inventory Net
InventoryNet
81693000
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
500489000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
218916000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
500489000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
206367000
CY2022Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12500000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9700000
CY2021Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
36572000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
50792000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
49997000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
47893000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
34574000
CY2022Q1 anip Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
61745000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
281573000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1700000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
400000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5800000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.223
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25900000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.277
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
100000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
49000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
66000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
7000
CY2022Q1 us-gaap Lease Cost
LeaseCost
192000
CY2021Q1 us-gaap Lease Cost
LeaseCost
56000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
344000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
428000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
412000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
190000
CY2022Q1 anip Lessee Operating Lease Liability To Be Paid Year Four And After
LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter
51000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1425000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
143000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1282000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
380000
CY2022Q1 anip Operating Lease Liability Other Noncurrent
OperatingLeaseLiabilityOtherNoncurrent
902000
CY2022Q1 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
400000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
31000000
CY2022Q1 anip Fair Value Measurement With Unobservable Inputs Reconciliation Measurement Period Adjustment
FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment
300000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
753000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
32053000
CY2022Q1 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
431000
CY2021Q4 us-gaap Interest Rate Derivative Liabilities At Fair Value
InterestRateDerivativeLiabilitiesAtFairValue
6790000
CY2022Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
100000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64477000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54521000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25897000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
76000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64477000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54521000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52713000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52671000

Files In Submission

Name View Source Status
0001023024-22-000008-index-headers.html Edgar Link pending
0001023024-22-000008-index.html Edgar Link pending
0001023024-22-000008.txt Edgar Link pending
0001023024-22-000008-xbrl.zip Edgar Link pending
anip-20220331.xsd Edgar Link pending
anip-20220331ex10114ef8b.htm Edgar Link pending
anip-20220331ex1026cf953.htm Edgar Link pending
anip-20220331ex311b22695.htm Edgar Link pending
anip-20220331ex31204809f.htm Edgar Link pending
anip-20220331ex3210b156d.htm Edgar Link pending
anip-20220331x10q.htm Edgar Link pending
anip-20220331x10q_htm.xml Edgar Link completed
anip-20220331_cal.xml Edgar Link unprocessable
anip-20220331_def.xml Edgar Link unprocessable
anip-20220331_lab.xml Edgar Link unprocessable
anip-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending